Recent Vaccines against Emerging and Tropical Infectious Diseases.

Ismail Mazhar, Mir Muhammad Rai, Abdullah Ahmad, Natasha Nadeem, Aamir Shahid Javed, Hassan Mumtaz
Author Information
  1. Ismail Mazhar: Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
  2. Mir Muhammad Rai: Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
  3. Abdullah Ahmad: Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
  4. Natasha Nadeem: Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
  5. Aamir Shahid Javed: Department of Medicine, CMH Lahore Medical College and Institute of Dentistry, Lahore, Pakistan.
  6. Hassan Mumtaz: Department of Data Analytics, BPP University London, UK.

Abstract

Emerging diseases, re-emerging diseases and tropical diseases are a slowly progressing problem globally. This may in part be the result of shifting population, growing poverty, inadequate distribution of resources, or even complacency against personal hygiene. As a result of the low income and low standards of health in developing countries, they provide the perfect breeding grounds for the pathogens and parasites that are the root cause of Neglected Tropical diseases (NTDs). In the case of emerging diseases, most are of zoonotic origin and the recent COVID-19 pandemic is a key example. However, it is not just new diseases but re-emerging diseases such as Influenza that highlight the relentless nature of these infections. Vaccines represent the ultimate safety net against these diseases by bolstering immune systems and lowering subsequent mortality and morbidity of these conditions. In fact, against diseases with high mortalities such as AIDS, Hepatitis, and Malaria, vaccine development has markedly reduced mortality and prolonged life expectancy of those afflicted with these conditions. However, this research highlights the importance of enhancing vaccine efficacy and response. The review further underscores the necessity of research, the timing of vaccine administration, effective resource management by governments, and the perception of the population. Therefore, the review offers valuable insights for the medical community and the pharmaceutical industry in improving research and management to maximize the potential of vaccines.

Keywords

References

  1. Acta Trop. 2020 Apr;204:105355 [PMID: 31991114]
  2. Vaccine. 2012 Sep 28;30(44):6225-9 [PMID: 22902680]
  3. Front Immunol. 2020 Sep 30;11:576748 [PMID: 33133094]
  4. Vet Parasitol. 2019 Mar;267:90-98 [PMID: 30878093]
  5. Indian J Dermatol Venereol Leprol. 2020 Mar-Apr;86(2):115-123 [PMID: 31975697]
  6. Int J Environ Res Public Health. 2023 Sep 27;20(19): [PMID: 37835112]
  7. Transbound Emerg Dis. 2022 Mar;69(2):254-267 [PMID: 33527632]
  8. Vaccines (Basel). 2022 Aug 25;10(9): [PMID: 36146463]
  9. Onderstepoort J Vet Res. 2002 Mar;69(1):95-8 [PMID: 12092782]
  10. J Med Microbiol. 2022 Dec;72(12): [PMID: 36748539]
  11. Exp Parasitol. 2020 Mar;210:107849 [PMID: 32027892]
  12. Semin Immunopathol. 2020 Jun;42(3):355-371 [PMID: 32076812]
  13. Vaccine. 2020 Jun 15;38(29):4584-4591 [PMID: 32417142]
  14. Vaccine. 2019 Jun 12;37(27):3505-3519 [PMID: 31103364]
  15. PLoS Negl Trop Dis. 2019 Jul 18;13(7):e0007407 [PMID: 31318857]
  16. Hum Vaccin Immunother. 2018;14(9):2128-2131 [PMID: 29393710]
  17. PLoS Negl Trop Dis. 2022 Aug 17;16(8):e0010679 [PMID: 35976975]
  18. Nature. 2021 Jul;595(7867):361-369 [PMID: 34262215]
  19. Parasitol Res. 2013 Oct;112(10):3635-43 [PMID: 23949241]
  20. Expert Rev Vaccines. 2021 Nov;20(11):1471-1482 [PMID: 34633881]
  21. BMC Immunol. 2023 Jan 5;24(1):1 [PMID: 36604615]
  22. JAMA. 2018 May 15;319(19):1973 [PMID: 29800221]
  23. NPJ Vaccines. 2019 Oct 18;4:44 [PMID: 31646004]
  24. Vaccine. 2011 Apr 12;29(17):3222-9 [PMID: 21354483]
  25. Parasitol Res. 2019 Dec;118(12):3419-3427 [PMID: 31724067]
  26. Lancet. 2017 Feb 4;389(10068):505-518 [PMID: 28017403]
  27. Nat Microbiol. 2018 May;3(5):556-562 [PMID: 29632370]
  28. Curr Opin Virol. 2019 Aug;37:105-111 [PMID: 31472333]
  29. Vaccine. 2019 Nov 28;37(50):7289-7294 [PMID: 28111145]
  30. Parasit Vectors. 2023 Oct 24;16(1):380 [PMID: 37876008]
  31. Nat Microbiol. 2021 Feb;6(2):187-195 [PMID: 33257849]
  32. J Infect Dis. 2022 Aug 26;226(3):528-540 [PMID: 35363871]
  33. Infect Dis Poverty. 2020 Jan 28;9(1):10 [PMID: 31987053]
  34. Expert Rev Vaccines. 2016 Sep;15(9):1135-50 [PMID: 27136941]
  35. Microorganisms. 2021 Mar 21;9(3): [PMID: 33801015]
  36. Expert Rev Vaccines. 2021 Nov;20(11):1447-1458 [PMID: 34379534]
  37. Vaccines (Basel). 2020 Sep 22;8(3): [PMID: 32971734]
  38. Emerg Infect Dis. 2019 Jun;25(6):1144-1152 [PMID: 31107231]
  39. Nature. 2022 Mar;603(7900):259-264 [PMID: 35264756]
  40. Viruses. 2012 Oct 29;4(11):2514-57 [PMID: 23202493]
  41. Microb Pathog. 2021 Jun;155:104859 [PMID: 33845124]
  42. PLoS One. 2016 Nov 28;11(11):e0167059 [PMID: 27893778]
  43. Front Immunol. 2020 Jun 19;11:1246 [PMID: 32636844]
  44. Vaccine. 2017 Jul 24;35(33):4064-4071 [PMID: 28647170]
  45. Front Cell Infect Microbiol. 2022 Apr 04;12:869039 [PMID: 35444961]
  46. J Am Acad Dermatol. 2020 Mar;82(3):533-548 [PMID: 31310840]
  47. Vaccine. 2019 May 27;37(24):3234-3240 [PMID: 31036453]
  48. Microbes Infect. 2019 Aug - Sep;21(7):278-286 [PMID: 30817995]
  49. Comput Struct Biotechnol J. 2022 Oct 07;20:5574-5585 [PMID: 36284708]
  50. Vet Parasitol. 2021 Jan;289:109340 [PMID: 33373968]
  51. Annu Rev Virol. 2020 Sep 29;7(1):447-473 [PMID: 32991264]
  52. PLoS Negl Trop Dis. 2019 May 28;13(5):e0007450 [PMID: 31136572]
  53. Immunol Rev. 2011 Jan;239(1):237-70 [PMID: 21198676]
  54. Lancet Infect Dis. 2019 Oct;19(10):1091-1100 [PMID: 31416692]
  55. Infect Dis Poverty. 2017 Sep 27;6(1):147 [PMID: 28950893]
  56. Expert Rev Vaccines. 2022 Oct;21(10):1419-1428 [PMID: 35962475]
  57. J Infect Dis. 2019 Apr 8;219(8):1187-1197 [PMID: 30407513]
  58. Vaccine. 2021 Dec 8;39(50):7238-7252 [PMID: 34119347]
  59. Sci Rep. 2019 Mar 13;9(1):4409 [PMID: 30867498]
  60. Hum Vaccin Immunother. 2020 Aug 2;16(8):1841-1850 [PMID: 31995448]
  61. Vaccine. 2021 May 21;39(22):2965-2975 [PMID: 33771390]
  62. Diagnostics (Basel). 2023 Aug 19;13(16): [PMID: 37627967]
  63. PLoS Negl Trop Dis. 2025 Feb 20;19(2):e0011718 [PMID: 39977439]
  64. J Parasit Dis. 2021 Jun;45(2):557-580 [PMID: 33935395]
  65. NPJ Vaccines. 2019 Mar 22;4:13 [PMID: 30911415]
  66. Parasitol Int. 2021 Aug;83:102353 [PMID: 33872795]
  67. Front Immunol. 2022 Mar 29;13:862491 [PMID: 35422800]
  68. J Vector Borne Dis. 2023 Apr-Jun;60(2):125-141 [PMID: 37417162]
  69. Acta Trop. 2022 Apr;228:106323 [PMID: 35065013]
  70. Transbound Emerg Dis. 2021 May;68(3):1080-1096 [PMID: 32762075]
  71. Bioimpacts. 2019;9(3):131-144 [PMID: 31508329]
  72. MMWR Morb Mortal Wkly Rep. 2022 Nov 25;71(47):1496-1502 [PMID: 36417302]
  73. Front Public Health. 2022 Dec 07;10:1054502 [PMID: 36568750]
  74. PLoS Negl Trop Dis. 2021 Jan 26;15(1):e0008812 [PMID: 33497377]
  75. Front Cell Infect Microbiol. 2023 Oct 18;13:1281823 [PMID: 37920447]
  76. Expert Rev Vaccines. 2022 Jun;21(6):771-781 [PMID: 35470769]
  77. Acta Trop. 2019 Dec;200:105168 [PMID: 31513763]
  78. Pathogens. 2020 Nov 23;9(11): [PMID: 33238479]
  79. Expert Rev Vaccines. 2021 Nov;20(11):1431-1446 [PMID: 34511000]
  80. Immunol Lett. 2019 Nov;215:1-11 [PMID: 31026485]
  81. Hum Vaccin Immunother. 2019;15(10):2269-2285 [PMID: 31368826]
  82. PLoS Negl Trop Dis. 2019 May 30;13(5):e0007413 [PMID: 31145733]
  83. Lancet Infect Dis. 2020 Apr;20(4):445-454 [PMID: 32027842]
  84. J Fungi (Basel). 2023 May 31;9(6): [PMID: 37367569]
  85. Front Immunol. 2018 Jun 26;9:1432 [PMID: 29997617]
  86. Am J Clin Dermatol. 2022 Nov;23(6):823-840 [PMID: 36103050]
  87. Front Immunol. 2018 Jul 02;9:1520 [PMID: 30013570]
  88. Mol Immunol. 2020 Apr;120:146-163 [PMID: 32126449]
  89. Vaccines (Basel). 2022 Oct 25;10(11): [PMID: 36366303]
  90. Clin Vaccine Immunol. 2006 Nov;13(11):1267-77 [PMID: 16988008]
  91. Front Immunol. 2021 Mar 04;12:635985 [PMID: 33746974]
  92. Vaccine. 2016 Jan 20;34(4):523-530 [PMID: 26706271]
  93. Epidemiol Rev. 2019 Jan 31;41(1):1-5 [PMID: 31680167]
  94. Acta Trop. 2020 Mar;203:105309 [PMID: 31862466]
  95. Front Immunol. 2020 Sep 30;11:583077 [PMID: 33101309]
  96. Vaccine. 2018 Feb 8;36(7):958-968 [PMID: 29373193]
  97. Hum Vaccin Immunother. 2019;15(10):2359-2377 [PMID: 31589088]
  98. Biochim Biophys Acta Mol Basis Dis. 2020 May 1;1866(5):165658 [PMID: 31904415]
  99. Front Immunol. 2021 Dec 01;12:778840 [PMID: 34925353]
  100. J Virol. 2010 Nov;84(21):11089-100 [PMID: 20739514]
  101. Vaccine. 2010 Dec 16;29(2):304-13 [PMID: 21034824]
  102. Emerg Infect Dis. 2024 May;30(5):864-873 [PMID: 38666553]

Word Cloud

Created with Highcharts 10.0.0diseasesVaccinesvaccineresearchEmergingre-emergingtropicalresultpopulationlowTropicalemergingHowevermortalityconditionsreviewmanagementslowlyprogressingproblemgloballymaypartshiftinggrowingpovertyinadequatedistributionresourcesevencomplacencypersonalhygieneincomestandardshealthdevelopingcountriesprovideperfectbreedinggroundspathogensparasitesrootcauseNeglectedNTDscasezoonoticoriginrecentCOVID-19pandemickeyexamplejustnewInfluenzahighlightrelentlessnatureinfectionsrepresentultimatesafetynetbolsteringimmunesystemsloweringsubsequentmorbidityfacthighmortalitiesAIDSHepatitisMalariadevelopmentmarkedlyreducedprolongedlifeexpectancyafflictedhighlightsimportanceenhancingefficacyresponseunderscoresnecessitytimingadministrationeffectiveresourcegovernmentsperceptionThereforeoffersvaluableinsightsmedicalcommunitypharmaceuticalindustryimprovingmaximizepotentialvaccinesRecentInfectiousDiseases

Similar Articles

Cited By

No available data.